Hematopoietic Stem Cell Transplantation Positively Affects the Natural History of Cancer in Nijmegen Breakage Syndrome
Overview
Authors
Affiliations
Purpose: Nijmegen breakage syndrome (NBS) is a DNA repair disorder with a high predisposition to hematologic malignancies.
Experimental Design: We describe the natural history of NBS, including cancer incidence, risk of death, and the potential effectiveness of hematopoietic stem cell transplantation (HSCT) in preventing both pathologies: malignancy and immunodeficiency.
Results: Among 241 patients with NBS enrolled in the study from 11 countries, 151 (63.0%) patients were diagnosed with cancer. Incidence rates for primary and secondary cancer, tumor characteristics, and risk factors affecting overall survival (OS) were estimated. The cumulative cancer incidence was 40.21% ± 3.5% and 77.78% ± 3.4% at 10 years and 20 years of follow-up, respectively. Most of the tumors = 95 (62.9%) were non-Hodgkin lymphomas. Overall, 20 (13.2%) secondary malignancies occurred at a median age of 18 (interquartile range, 13.7-21.5) years. The probability of 20-year overall survival (OS) for the whole cohort was 44.6% ± 4.5%. Patients who developed cancer had a shorter 20-year OS than those without malignancy (29.6% vs. 86.2%; < 10). A total of 49 patients with NBS underwent HSCT, including 14 patients transplanted before malignancy. Patients with NBS with diagnosed cancer who received HSCT had higher 20-year OS than those who did not (42.7% vs. 30.3%; = 0.038, respectively). In the group of patients who underwent preemptive transplantation, only 1 patient developed cancer, which is 6.7 times lower as compared with nontransplanted patients [incidence rate ratio 0.149 (95% confidence interval, 0.138-0.162); < 0.0001].
Conclusions: There is a beneficial effect of HSCT on the long-term survival of patients with NBS transplanted in their first complete remission of cancer.
Cancer Trends in Inborn Errors of Immunity: A Systematic Review and Meta-Analysis.
Fekrvand S, Abolhassani H, Esfahani Z, Fard N, Amiri M, Salehi H J Clin Immunol. 2024; 45(1):34.
PMID: 39466473 DOI: 10.1007/s10875-024-01810-w.
Nakano Y, Kuiper R, Nichols K, Porter C, Lesmana H, Meade J Clin Cancer Res. 2024; 30(22):5009-5020.
PMID: 39264246 PMC: 11705613. DOI: 10.1158/1078-0432.CCR-24-1098.
Pastorczak A, Urbanska Z, Styka B, Miarka-Walczyk K, Sedek L, Wypyszczak K Leukemia. 2024; 38(11):2344-2354.
PMID: 39192035 PMC: 11518979. DOI: 10.1038/s41375-024-02370-z.
Nijmegen breakage syndrome: 25-year experience of diagnosis and treatment in Ukraine.
Boyarchuk O, Kostyuchenko L, Akopyan H, Bondarenko A, Volokha A, Hilfanova A Front Immunol. 2024; 15:1428724.
PMID: 39007137 PMC: 11239363. DOI: 10.3389/fimmu.2024.1428724.
Fasshauer M, Dinges S, Staudacher O, Voller M, Stittrich A, von Bernuth H Front Pediatr. 2024; 12:1386959.
PMID: 38933494 PMC: 11203071. DOI: 10.3389/fped.2024.1386959.